Treg dysfunction, down-regulation of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), receptor activator of nuclear factor-kappa B ligand (RANKL), Forkhead box protein P3 (FoxP3), and IL-10 indicate the role of Treg among MG patients [82, 83]. This evidence concerns the gene IL10 and myasthenia gravis.